缅北禁地

Background

My PhD was completed in Graham Goodwin's laboratory at the Chester Beatty Laboratories, Institute of Cancer Research, London in 1990. This work concerned the investigation of chicken beta globin gene expression and resulted in the identification of the transcription factor that later became known as GATA1 (known as EF1 in the Goodwin lab).

From 1990 to 1996 I was a postdoctoral researcher in Gary Nabel's laboratory, at the Howard Hughes Medical Institute at the University of Michigan, where my interest in the NF-kappaB transcription factor family began. Much of this work concerned the ability of NF-appaB to function as a regulator of human immunodeficiency virus (HIV) 1.

Previous Positions

October 1986 - March 1990: Ph.D. student in the laboratory of Dr. Graham Goodwin, Chester Beatty Laboratories, Institute of Cancer Research.

March 1990- March 1996: Postdoctoral Fellow in the laboratory of Prof. Gary J. Nabel, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, MI, USA.

March 1996 – Nov 2007: Lecturer and then Reader, Principal Investigator, University of Dundee

October 1996 - September 2005: Royal Society University Research Fellow

Nov 2007 – June 2008: Professor of Gene Expression and Signalling in the Wellcome Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee

July 2008 – March 2010: Professor of Molecular Cell Biology, Department of Cellular & Molecular Medicine, University of Bristol

April 2010 - present: Professor of Gene Expression and Signalling, 缅北禁地

November 2019 - present: Deputy Dean - Biosciences Institute

November 2019 - present: Theme Lead - Cell Signalling

Regulation of cancer cell proliferation and survival by NF-kappaB

NF-kappaB is a collective name for the complexes formed by the multigene NF-kappaB-Rel family which function as DNA-binding proteins and transcription factors. NF-kappaB subunits induce the expression of a wide range of genes encoding proteins involved in inflammation, regulation of cell death, cell adhesion, proliferation and other critical cellular functions. Aberrant activation of NF-kappaB therefore leads to overproduction of these proteins, which can contribute to many types of human disease. In particular, NF-kappaB has an important role in many inflammatory diseases and cancer. Moreover, NF-kappaB is activated by many cancer therapies and can have an inhibitory effect on these treatments. The pathways regulating NF-kappaB are therefore thought to be good targets for the development of new anti-inflammatory and anti-cancer drugs.

My laboratory is interested in how NF-kappaB subunits are regulated by oncogenes, tumour suppressors and stimuli associated with cancer development and therapy. A theme emerging from these studies has been the importance of context for NF-kappaB activity and how subunits can both repress as well as activate gene targets, leading to alterations in cell fate. We have revealed the importance of post-translational modifications in controlling these activities and argued that the activity of parallel signalling pathways have a critical role in determining NF-kappaB dependent transcriptional output. Based on this work, together with that from other researchers, we propose that the concerted action of tumour suppressors functions to keep the oncogenic activities of NF-kappaB subunits in check and that loss of tumour suppressor activity during tumour development is required to unleash these anti apoptotic and pro-metastatic activities in malignant cancer cells.

CMB2001:Control of Eukaryotic Gene Expression

BGM2002:Biochemistry and Genetics of Signalling and the Cell Cycle

BGM3065:Biochemistry of Cancer and Chronic Diseases

MMB8050: Therapeutic Applications of Cell Signalling

• Madgwick S, Luli S, Sellier H, Butterworth JA, Leslie J, Moore AJ, Corbin EK, Yemm AI, Chiremba RT, Tiniakos D, Oakley F, Perkins ND, Hunter JE. . Biochemical Journal 2022, 479(19), 2115-2130.
• Leslie J, Hunter JE, Collins A, Rushton A, Russell LG, Ramon-Gil E, Laszczewska M, McCain M, Zaki MYW, Knox A, Seow Y, Sabater L, Geh D, Perkins ND, Reeves HL, Tiniakos D, Mann DA, Oakley F. . Hepatology 2023, 78(4), 1050-1063.
• Hunter JE, Campbell AE, Butterworth JA, Sellier H, Hannaway NL, Luli S, Floudas A, Kenneth NS, Moore AJ, Brownridge PJ, Thomas HD, Coxhead J, Taylor L, Leary P, Hasoon MSR, Knight AM, Garrett MD, Collins I, Eyers CE, Perkins ND. . Biochemical Journal 2022, 479(19), 2087-2113.
• Hunter JE, Campbell AE, Hannaway NL, Kerridge S, Luli S, Butterworth JA, Sellier H, Mukherjee R, Dhillon N, Sudhindar PD, Shukla R, Brownridge PJ, Bell HL, Coxhead J, Taylor L, Leary P, Hasoon MSR, Collins I, Garrett MD, Eyers CE, Perkins ND. . Biochemical Journal 2022, 479(19), 2063-2086.
• Hunter JE, Campbell AE, Kerridge S, Fraser C, Hannaway NL, Luli S, Ivanova I, Brownridge PJ, Coxhead J, Taylor L, Leary P, Hasoon MSR, Eyers CE, Perkins ND. . Biochemical Journal 2022, 479(19), 2131-2151.
• Sandhu S, Sou IF, Hunter JE, Salmon L, Wilson CL, Perkins ND, Hunter N, Davies OR, McClurg UL. . Communications Biology 2021, 4(1), 1371.
• Campbell AE, Franco CF, Su L-I, Corbin EK, Perkins S, Kalyuzhnyy A, Jones AR, Brownridge PJ, Perkins ND, Eyers CE. . Biochemical Journal 2021, 478(3), 533-551.
• Dura G, Peters DT, Waller H, Yemm AI, Perkins ND, Ferreira AM, Crespo-Cuadrado M, Lakey JH, Fulton DA. . Chem 2020, 6(11), 3132-3151.
• Smith ALM, Whitehall JC, Bradshaw C, Gay D, Robertson F, Blain AP, Hudson G, Pyle A, Houghton D, Hunt M, Sampson JN, Stamp C, Mallett G, Amarnath S, Leslie J, Oakley F, Wilson L, Baker A, Russell OM, Johnson R, Richardson CA, Gupta B, McCallum I, McDonald SAC, Kelly S, Mathers JC, Heer R, Taylor RW, Perkins ND, Turnbull DM, Sansom OJ, Greaves LC. . Nature Cancer 2020, 1, 976-989.
• Ivanova IG, Perkins ND. . Bioscience Reports 2019, 39(9), BSR20192101.
• Al-Jawdah AD, Ivanova IG, Waller H, Perkins ND, Lakey JH, Peters DT. . BMC Microbiology 2019, 19(1), 68.
• Szoltysek K, Janus P, Zajac G, Stokowy T, Walaszczyk A, Widlak W, Wojtas B, Gielniewski B, Cockell S, Perkins ND, Kimmel M, Widlak P. . BMC Genomics 2018, 19(1), 813.
• Perkins ND. . EMBO Journal 2018, 37(24), e101084.
• Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, Tiniakos D, Cockell SJ, Mann DA, Oakley F, Perkins ND. . Oncogene 2016, 35(35), 4623-4632.
• Hunter JE, Leslie J, Perkins ND. . British Journal of Cancer 2016, 114(1), 1-6.
• Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, Brandon AKD, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD. . Oncotarget 2016, 7(3), 2329-2342.
• Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND. . Oncogene 2016, 35(26), 3476-3484.
• Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong PP, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG, Hodivala-Dilke KM. . Nature 2014, 514(7520), 112-116.
• Ledoux AC, Perkins ND. . Biochemical Society Transactions 2014, 42(1), 76-81.
• Harte MT, Gorski JJ, Savage KI, Purcell JW, Barros EW, Burn PM, McFarlane C, Mullan PB, Kennedy RD, Perkins ND, Harkin DP. . Oncogene 2014, 33(6), 713-723.
• Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ, Jat PS, Willmore E, Perkins ND. . PLoS Genetics 2014, 10(9), e1004642.
• Hunter JE, Butterworth J, Perkins ND, Bateson M, Richardson CA. . British Journal of Cancer 2014, 110, 928-934.
• Perkins ND. . Cancer Cell 2013, 24(2), 139-140.
• Yamada K, Ono M, Perkins ND, Rocha S, Lamond AI. . Molecular Cell 2013, 49(5), 922-933.
• Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, Fisher A, O'Reilly S, van Laar JM, White SA, Perkins ND, Burt AD, Mann DA, Oakley F. . Hepatology 2013, 57(2), 817-828.
• Ledoux AC, Sellier H, Gillies K, Iannetti A, James J, Perkins ND. . Cell Cycle 2013, 12(18), 3052-3062.
• Southern SL, Collard TJ, Urban BC, Skeen VR, Smartt HJ, Hague A, Oakley F, Townsend PA, Perkins ND, Paraskeva C, Williams AC. . Oncogene 2012, 31(22), 2761-2772.
• Perkins ND. . Molecular Cell 2012, 45(1), 1-3.
• Johnson RF, Perkins ND. . Trends in Biochemical Sciences 2012, 37(8), 317-324.
• Perkins ND. . Nature Reviews. Cancer 2012, 12(2), 121-132.
• Johnson RF, Witzel II, Perkins ND. . Cancer Research 2011, 71(16), 5588-5597.
• Msaki A, Sanchez AM, Koh LF, Barre B, Rocha S, Perkins ND, Johnson RF. . Molecular Biology of the Cell 2011, 22(17), 3032-3040.
• O'Shea JM, Perkins ND. . Biochemical Journal 2010, 426(3), 345-354.
• Bracken CP, Wall SJ, Barré B, Panov KI, Ajuh PM, Perkins ND. . Cancer Research 2008, 68(18), 7621-7628.
• O'Shea JM, Perkins ND. . Biochemical Society Transactions 2008, 36(4), 603-608.
• Perkins ND. . Nature Reviews Molecular Cell Biology 2007, 8(1), 49-62.
• Tergaonkar V, Perkins ND. . Molecular Cell 2007, 26(2), 158-159.
• McTavish N, Copeland LA, Saville MK, Perkins ND, Spruce BA. . Cell Death and Differentiation 2007, 14(9), 1700-1710.
• Roche KC, Rocha S, Bracken CP, Perkins ND. . Oncogene 2007, 26(31), 4523-4530.
• Sharif O, Bolshakov VN, Raines S, Newham P, Perkins ND. . BMC Immunology 2007, 8, 1.
• Campbell KJ, Witty JM, Rocha S, Perkins ND. . Cancer Research 2006, 66(2), 929-935.
• Campbell KJ, O'Shea JM, Perkins ND. . BMC Cancer 2006, 6, 101.
• Perkins ND, Gilmore TD. . Cell Death and Differentiation 2006, 13(5), 759-772.
• Perkins ND. . Oncogene 2006, 25(51), 6717-6730.
• Schumm K, Rocha S, Caamano J, Perkins ND. . The EMBO Journal 2006, 25(20), 4820-4832.
• Fujii M, Lyakh LA, Bracken CP, Fukuoka J, Hayakawa M, Tsukiyama T, Soil SJ, Harris M, Rocha S, Roche KC, Tominaga SI, Jen J, Perkins ND, Lechleider RJ, Roberts AB. . Molecular Cell 2006, 24(5), 771-783.
• Rocha S, Perkins ND. . Cell Cycle 2005, 4(6), 756-759.
• Garcia-Wilson E, Perkins ND. . Cell Cycle 2005, 4(8), 1113-1119.
• Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. . The EMBO Journal 2005, 24(6), 1157-1169.
• Bates GJ, Nicol SM, Wilson BJ, Jacobs AMF, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV. . The EMBO Journal 2005, 24(3), 543-553.